What ResMed's latest 10-Q says: 7 signals
ResMed filed its latest 10-Q with the SEC on Apr 30, 2026. It discusses platform strategy, inflation impact and logistics challenge.
Public (RMD)Medical Equipment Manufacturing5,001 to 10,000 employeesresmed.comLinkedIn
- Filed
- Apr 30, 2026
- Filings
- 2
- Signals
- 19
10-Q · latest 10
What ResMed's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 7 signals
ResMed commits to $984M in purchase obligations for the upcoming year
The company has disclosed nearly $1 billion in contractual purchase obligations due within the next 12 months, signaling a massive, planned spend on its supply chain and manufacturing operations.
$984M
Purchase obligations due by March 31, 2027
ResMed using $3.4B currency swap program to manage risk from international manufacturing.
With manufacturing concentrated in Australia and Singapore, ResMed faces significant financial risk from currency fluctuations.
$3.4B
Notional value of outstanding foreign cross-currency swaps
MUFG Union BankWestpac Banking Corporation
ResMed warns that inflation may adversely affect gross margin and operating results.
The company explicitly states that rising costs for products, freight, and overhead may negatively impact its ability to maintain current margin levels, creating a need for cost-reduction and efficiency solutions.
ResMed flags potential inability to pass on rising costs through price increases.
The company's statement on inflation indicates a potential lack of pricing power, which could compress margins.
ResMed cites inflation impacting product costs, freight, and overhead.
The company is facing rising costs for its products, shipping, and general overhead due to inflation, which could negatively impact operating results and gross margins.
- SEC EDGAR
10-Q
Filed · 12 signals
Company has $861M in purchase obligations, with $840M due in 2026
ResMed has committed to $861.2 million in purchase obligations, with the vast majority ($839.5 million) due within the next year.
$861.2M
Total purchase obligations
Accelerated share buybacks with $325M spent in last six months
ResMed significantly increased its share repurchase activity, spending $325 million in the six months ending Dec 31, 2025, up from $125 million the prior year.
$325M
Share repurchases during the six months ended Dec 31, 2025
ResMed's allowance for doubtful accounts surged 30% in 6 months to $29.2M.
The rapid increase in expected bad debt from $22.4M to $29.2M indicates growing difficulty in collecting payments from customers.
$29.2M
Allowance for doubtful accounts as of December 31, 2025
30%
Increase in allowance for doubtful accounts over six months
SaaS business revenue grew 17% in the quarter, outpacing overall company growth.
ResMed's Software as a Service (SaaS) segment grew 17% year-over-year for the quarter, significantly faster than the company's overall growth.
17%
YoY revenue growth for the SaaS business in the three months ended December 31, 2025
SaaSsoftware
Managing nearly $3B in complex foreign currency hedging contracts
ResMed is managing a massive and complex currency hedging program with notional values of $1.12B in cross-currency swaps and $1.79B in non-designated hedges.
$2.9B
Total notional value of outstanding currency hedges (swaps + non-designated) as of Dec 31, 2025
Mufg Union Bank Na And Westpac Banking Corporation
Showing 10 of 19 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
ResMed earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Actively deploying ML, AI, and Generative AI in digital health products.ResMed is rolling out AI-powered features like 'Dawn' (a generative AI assistant) and 'Comfort Match' (an AI-enabled settings tool) to enhance patient support and adherence. This indicates active budget and resource allocation for AI development, data infrastructure, and cloud services. | |
| Experiencing massive growth in API calls, focusing on interoperability.The company's digital health ecosystem handled over 3 billion API calls in the quarter, a 40% year-over-year increase, highlighting a focus on data interoperability. This massive data volume signals needs for robust cloud infrastructure, data management, analytics, and API security solutions. | |
| Launching multiyear programs for planning systems and automationTo drive operating leverage, ResMed is implementing multiyear productivity programs focused on improved planning systems and large-scale automation. This signals budget and active evaluation for enterprise resource planning (ERP), supply chain planning software, and factory automation technologies. | |
| Restructuring software portfolio to focus on high-growth SaaSResMed is actively reallocating investment within its Residential Care Software (RCS) division, focusing on high-growth SaaS platforms (MEDIFOX, Brightree, MatrixCare) while reducing exposure to low-margin services. This portfolio management initiative creates opportunities for vendors who can support the scaling of their core SaaS products. | |
| Delivered strong 9% revenue growth and returned $238M to shareholders.The company reported strong financial performance with 9% revenue growth and significant capital return to shareholders. This financial health and strong free cash flow demonstrates the capacity to fund strategic initiatives and new investments. | |
| Investing to accelerate growth in direct-to-consumer (DTC) Asian markets.The company is focused on accelerating growth in DTC markets including China, India, and Korea. This geographic expansion creates opportunities for vendors in international marketing, e-commerce platforms, and localized digital engagement. |
Signal API · MCP
Track ResMed with the Signal API
One POST /v1/companies/enrich call with resmed.com returns ResMed 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"resmed.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about ResMed 10-Q
When did ResMed file its latest 10-Q?
What did ResMed disclose in its latest 10-Q?
What did ResMed say on its recent earnings calls?
Where can I read ResMed's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .